Skip to main content
SpringerLink
Log in

Amyloid Imaging in Dementia and Neurodegenerative Disease

  • Chapter
  • First Online:
Hybrid PET/MR Neuroimaging

Abstract

Alzheimer’s disease (AD) accounts for 70% of dementia cases. Neuropsychological testing has limited sensitivity and specificity compared with the gold standard of histological examination postmortem. The neuropathological hallmarks of AD are β-amyloid peptide aggregates and hyperphosphorylated tau protein. Imaging using amyloid PET tracers allows the detection of amyloid deposition in vivo, serving as an important diagnostic tool. Several approved amyloid PET tracers are available with equivalent performance in clinical practice and vendor-specific image interpretation methodologies. In addition, amyloid PET imaging can play a role in discriminating between the various etiologic forms of neurodegeneration, particularly in the setting of mixed pathologies. Amyloid co-pathology has been reported with other neurodegenerative diseases such as dementia of Lewy bodies or associated with other pathologies that can contribute to patient symptoms, such as vascular dementia. The presence of multiple comorbid neuropathologies can erroneously lead to the diagnosis of and treatment of AD when the cause of the symptoms is related to mixed dementia, limiting therapeutic efficacy in this group. More importantly, β-amyloid imaging has a clinical impact in 60–63% of cases, changing the suspected etiology from AD to non-AD in 25% of the patients. Several ongoing trials are evaluating the role of amyloid deposition in AD  pathophysiology and assessing anti-amyloid therapy efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263–9. https://doi.org/10.1016/j.jalz.2011.03.005.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ciccocioppo F, Bologna G, Ercolino E, Pierdomenico L, Simeone P, Lanuti P, et al. Neurodegenerative diseases as proteinopathies-driven immune disorders. Neural Regen Res. 2020;15(5):850–6. https://doi.org/10.4103/1673-5374.268971.

    Article  PubMed  Google Scholar 

  3. Villemagne VL, Ng S, Cappai R, Barnham KJ, Fodero-Tavoletti MT, Rowe CC, et al. La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. Neuroradiol J. 2006;19(4):453–74. https://doi.org/10.1177/197140090601900406.

    Article  CAS  PubMed  Google Scholar 

  4. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem. 2006;97(6):1700–25. https://doi.org/10.1111/j.1471-4159.2006.03989.x.

    Article  CAS  PubMed  Google Scholar 

  5. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71(4):266–73. https://doi.org/10.1097/NEN.0b013e31824b211b.

    Article  PubMed  Google Scholar 

  6. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669–78. https://doi.org/10.1016/S1474-4422(12)70142-4.

    Article  CAS  PubMed  Google Scholar 

  7. Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015;11(8):964–74. https://doi.org/10.1016/j.jalz.2015.02.004.

    Article  PubMed  Google Scholar 

  8. Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72(3):287–94. https://doi.org/10.1001/jamaneurol.2014.4144.

    Article  PubMed  Google Scholar 

  9. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59. https://doi.org/10.1007/BF00308809.

    Article  CAS  PubMed  Google Scholar 

  10. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306–19. https://doi.org/10.1002/ana.20009.

    Article  CAS  PubMed  Google Scholar 

  11. Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, et al. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem. 2008;105(4):1428–37. https://doi.org/10.1111/j.1471-4159.2008.05245.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(Pt 6):1630–45. https://doi.org/10.1093/brain/awn016.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130(Pt 10):2607–15. https://doi.org/10.1093/brain/awm191.

    Article  CAS  PubMed  Google Scholar 

  14. Okamura N, Suemoto T, Shimadzu H, Suzuki M, Shiomitsu T, Akatsu H, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004;24(10):2535–41. https://doi.org/10.1523/JNEUROSCI.4456-03.2004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12(6):584–95. https://doi.org/10.1176/appi.ajgp.12.6.584.

    Article  PubMed  Google Scholar 

  16. Wolk DA, Grachev ID, Buckley C, Arnold SE. F-18-flutemetamol amyloid imaging has strong concordance with cortical biopsy histopathology. Neurology. 2011;76(9):A661–A2.

    Google Scholar 

  17. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913–20. https://doi.org/10.2967/jnumed.109.069088.

    Article  CAS  PubMed  Google Scholar 

  18. Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, et al. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimers Dement (Amst). 2019;11:180–90. https://doi.org/10.1016/j.dadm.2018.12.008.

    Article  Google Scholar 

  19. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319–29. https://doi.org/10.1002/ana.22068.

    Article  PubMed  Google Scholar 

  20. Lowe VJ, Lundt E, Knopman D, Senjem ML, Gunter JL, Schwarz CG, et al. Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. Neuroimage Clin. 2017;16:295–302. https://doi.org/10.1016/j.nicl.2017.08.011.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rowe CC, Dore V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. (18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44(12):2053–9. https://doi.org/10.1007/s00259-017-3749-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Yeo JM, Waddell B, Khan Z, Pal S. A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease. Alzheimers Dement (Amst). 2015;1(1):5–13. https://doi.org/10.1016/j.dadm.2014.11.004.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med. 2007;48(4):547–52. https://doi.org/10.2967/jnumed.106.037762.

    Article  CAS  PubMed  Google Scholar 

  24. Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbetaben binding to beta-amyloid deposits in human brains. J Nucl Med. 2013;54(5):723–31. https://doi.org/10.2967/jnumed.112.107185.

    Article  CAS  PubMed  Google Scholar 

  25. Perani D, Schillaci O, Padovani A, Nobili FM, Iaccarino L, Della Rosa PA, et al. A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int. 2014;2014:785039. https://doi.org/10.1155/2014/785039.

    Article  PubMed  Google Scholar 

  26. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424–35. https://doi.org/10.1016/S1474-4422(11)70077-1.

    Article  CAS  PubMed  Google Scholar 

  27. Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41(7):1398–407. https://doi.org/10.1007/s00259-014-2753-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, et al. SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med. 2016;57(8):1316–22. https://doi.org/10.2967/jnumed.116.174615.

    Article  CAS  PubMed  Google Scholar 

  29. Lundeen TF, Seibyl JP, Covington MF, Eshghi N, Kuo PH. Signs and artifacts in amyloid PET. Radiographics. 2018;38(7):2123–33. https://doi.org/10.1148/rg.2018180160.

    Article  PubMed  Google Scholar 

  30. Barthel H, Seibyl J, Lammertsma AA, Villemagne VL, Sabri O. Exploiting the full potential of beta-amyloid and tau PET imaging for drug efficacy testing. J Nucl Med. 2020;61(8):1105–6. https://doi.org/10.2967/jnumed.119.228346.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54(9):1570–6. https://doi.org/10.2967/jnumed.112.113654.

    Article  CAS  PubMed  Google Scholar 

  32. Nayate AP, Dubroff JG, Schmitt JE, Nasrallah I, Kishore R, Mankoff D, et al. Use of standardized uptake value ratios decreases interreader variability of [18F] Florbetapir PET brain scan interpretation. AJNR Am J Neuroradiol. 2015;36(7):1237–44. https://doi.org/10.3174/ajnr.A4281.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Cummings J. The National Institute on Aging-Alzheimer's Association framework on Alzheimer's disease: application to clinical trials. Alzheimers Dement. 2019;15(1):172–8. https://doi.org/10.1016/j.jalz.2018.05.006.

    Article  PubMed  Google Scholar 

  34. Morris GP, Clark IA, Vissel B. Questions concerning the role of amyloid-beta in the definition, aetiology and diagnosis of Alzheimer's disease. Acta Neuropathol. 2018;136(5):663–89. https://doi.org/10.1007/s00401-018-1918-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of Amyloid Positron Emission Tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286–94. https://doi.org/10.1001/jama.2019.2000.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126–39. https://doi.org/10.1093/brain/aws125.

    Article  PubMed  Google Scholar 

  37. de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of Amyloid Positron Emission Tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort the ABIDE project. JAMA Neurol. 2018;75(9):1062–70. https://doi.org/10.1001/jamaneurol.2018.1346.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):18. https://doi.org/10.1186/s12929-019-0609-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L. Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer's disease. J Prev Alzheimers Dis. 2018;5(2):149–54. https://doi.org/10.14283/jpad.2018.18.

    Article  CAS  PubMed  Google Scholar 

  40. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med. 2013;54(3):476–90. https://doi.org/10.2967/jnumed.113.120618.

    Article  CAS  PubMed  Google Scholar 

  41. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med. 2013;54(7):1011–3. https://doi.org/10.2967/jnumed.113.127068.

    Article  PubMed  Google Scholar 

  42. Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, et al. AMYPAD diagnostic and patient management study: rationale and design. Alzheimers Dement. 2019;15(3):388–99. https://doi.org/10.1016/j.jalz.2018.09.003.

    Article  PubMed  Google Scholar 

  43. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446–52. https://doi.org/10.1212/01.wnl.0000228230.26044.a4.

    Article  CAS  PubMed  Google Scholar 

  44. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718–25. https://doi.org/10.1212/01.wnl.0000261919.22630.ea.

    Article  CAS  PubMed  Google Scholar 

  45. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939–49. https://doi.org/10.1001/jama.2015.4669.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Dickerson BC, McGinnis SM, Xia C, Price BH, Atri A, Murray ME, et al. Approach to atypical Alzheimer's disease and case studies of the major subtypes. CNS Spectr. 2017;22(6):439–49. https://doi.org/10.1017/S109285291600047X.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225–36. https://doi.org/10.1038/nrneurol.2018.9.

    Article  CAS  PubMed  Google Scholar 

  48. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351–7. https://doi.org/10.1016/s0197-4580(97)00056-0.

    Article  CAS  PubMed  Google Scholar 

  49. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122–31. https://doi.org/10.1002/ana.21843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Formaglio M, Costes N, Seguin J, Tholance Y, Le Bars D, Roullet-Solignac I, et al. In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. J Neurol. 2011;258(10):1841–51. https://doi.org/10.1007/s00415-011-6030-0.

    Article  PubMed  Google Scholar 

  51. Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA, et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol. 2010;68(4):545–8. https://doi.org/10.1002/ana.22099.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66(12):1537–44. https://doi.org/10.1001/archneurol.2009.285.

    Article  PubMed  Google Scholar 

  53. Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012;2(10):975–84. https://doi.org/10.4155/cli.12.93.

    Article  CAS  Google Scholar 

  54. Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013;110(47):E4502–9. https://doi.org/10.1073/pnas.1317918110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129(Pt 11):2856–66. https://doi.org/10.1093/brain/awl178.

    Article  PubMed  Google Scholar 

  56. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003;60(5):729–36. https://doi.org/10.1001/archneur.60.5.729.

    Article  PubMed  Google Scholar 

  57. Hammes J, Leuwer I, Bischof GN, Drzezga A, van Eimeren T. Multimodal correlation of dynamic [(18)F]-AV-1451 perfusion PET and neuronal hypometabolism in [(18)F]-FDG PET. Eur J Nucl Med Mol Imaging. 2017;44(13):2249–56. https://doi.org/10.1007/s00259-017-3840-z.

    Article  CAS  PubMed  Google Scholar 

  58. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3):358–68. https://doi.org/10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x.

    Article  CAS  PubMed  Google Scholar 

  59. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia. 2000;15(3):93–101.

    CAS  PubMed  Google Scholar 

  60. Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71(6):765–75. https://doi.org/10.1002/ana.22628.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012;66(2):185–98. https://doi.org/10.1111/j.1742-1241.2011.02845.x.

    Article  CAS  PubMed  Google Scholar 

  62. Blazhenets G, Ma YL, Sorensen A, Schiller F, Rucker G, Eidelberg D, et al. Predictive value of F-18-florbetapir and F-18-FDG PET for conversion from mild cognitive impairment to Alzheimer dementia. J Nucl Med. 2020;61(4):597–603. https://doi.org/10.2967/jnumed.119.230797.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Thomas DX, Bajaj S, McRae-McKee K, Hadjichrysanthou C, Anderson RM, Collinge J. Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer's disease neuropathology. Sci Rep. 2020;10(1):14579. https://doi.org/10.1038/s41598-020-71305-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Mackenzie IR, Munoz DG, Kusaka H, Yokota O, Ishihara K, Roeber S, et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol. 2011;121(2):207–18. https://doi.org/10.1007/s00401-010-0764-0.

    Article  PubMed  Google Scholar 

  65. Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77(23):2034–42. https://doi.org/10.1212/WNL.0b013e31823b9c5e.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Kantarci K, Lowe VJ, Chen Q, Przybelski SA, Lesnick TG, Schwarz CG, et al. beta-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology. 2020;94(3):e282–e91. https://doi.org/10.1212/WNL.0000000000008818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Mashima K, Ito D, Kameyama M, Osada T, Tabuchi H, Nihei Y, et al. Extremely low prevalence of amyloid positron emission tomography positivity in Parkinson's disease without dementia. Eur Neurol. 2017;77(5–6):231–7. https://doi.org/10.1159/000464322.

    Article  CAS  PubMed  Google Scholar 

  68. Schutz L, Lobsien D, Fritzsch D, Tiepolt S, Werner P, Schroeter ML, et al. Feasibility and acceptance of simultaneous amyloid PET/MRI. Eur J Nucl Med Mol Imaging. 2016;43(12):2236–43. https://doi.org/10.1007/s00259-016-3462-x.

    Article  CAS  PubMed  Google Scholar 

  69. Okazawa H, Ikawa M, Jung M, Maruyama R, Tsujikawa T, Mori T, et al. Multimodal analysis using [(11)C]PiB-PET/MRI for functional evaluation of patients with Alzheimer's disease. EJNMMI Res. 2020;10(1):30. https://doi.org/10.1186/s13550-020-00619-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Vercher-Conejero JL, Rubbert C, Kohan AA, Partovi S, O'Donnell JK. Amyloid PET/MRI in the differential diagnosis of dementia. Clin Nucl Med. 2014;39(6):e336–9. https://doi.org/10.1097/RLU.0b013e31829b9e5f.

    Article  PubMed  Google Scholar 

  71. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Yan S, Qian T, Marechal B, Kober T, Zhang X, Zhu J, et al. Test-retest variability of brain morphometry analysis: an investigation of sequence and coil effects. Ann Transl Med. 2020;8(1):12. https://doi.org/10.21037/atm.2019.11.149.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032–42. https://doi.org/10.1002/ana.22333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, et al. Partial volume correction in quantitative amyloid imaging. NeuroImage. 2015;107:55–64. https://doi.org/10.1016/j.neuroimage.2014.11.058.

    Article  CAS  PubMed  Google Scholar 

  75. Erlandsson K, Dickson J, Arridge S, Atkinson D, Ourselin S, Hutton BF. MR imaging-guided partial volume correction of PET data in PET/MR imaging. PET Clin. 2016;11(2):161–77. https://doi.org/10.1016/j.cpet.2015.09.002.

    Article  PubMed  Google Scholar 

  76. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67(6):584–7. https://doi.org/10.1016/j.biopsych.2009.08.024.

    Article  CAS  PubMed  Google Scholar 

  77. Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011;134(Pt 6):1635–46. https://doi.org/10.1093/brain/awr066.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Chen KT, Schürer M, Ouyang J, Koran MEI, Davidzon G, Mormino E, et al. Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning. Eur J Nucl Med Mol Imaging. 2020;47(13):2998–3007. https://doi.org/10.1007/s00259-020-04897-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA

    Maria Rosana Ponisio & Tammie L. S. Benzinger

  2. Richard L. Roudebush VA Medical Center, Department of Nuclear Medicine, Indianapolis, IN, USA

    Pooya Iranpour

Authors
  1. Maria Rosana Ponisio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pooya Iranpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tammie L. S. Benzinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Rosana Ponisio .

Editor information

Editors and Affiliations

  1. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Feinstein Institutes for Medical Research, Manhasset, NY, USA

    Ana M. Franceschi

  2. Stony Brook University Hospital, Stony Brook, NY, USA

    Dinko Franceschi

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ponisio, M.R., Iranpour, P., Benzinger, T.L.S. (2022). Amyloid Imaging in Dementia and Neurodegenerative Disease. In: Franceschi, A.M., Franceschi, D. (eds) Hybrid PET/MR Neuroimaging. Springer, Cham. https://doi.org/10.1007/978-3-030-82367-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-82367-2_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-82366-5

  • Online ISBN: 978-3-030-82367-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation